Rarely seen ‘supergiant' deep-sea cousin of woodlice is actually quite common, study finds
A rarely spotted 'supergiant' crustacean related to woodlice is actually a common inhabitant of the sea floor, a new study finds.
The deep-sea creature, Alicella gigantea, which can grow up to 34cm long, is the largest-known species of the amphipods.
Amphipod is among the most diverse group of crustaceans, with over 10,000 extant species, including woodlice, shrimps, and lobsters. Amphipods are known to inhabit all aquatic environments worldwide.
Alicella gigantea, commonly known as the 'supergiant amphipod', has long attracted attention due to its gigantism. It was first filmed in the 1970s at a depth of over 5,300m in the North Pacific but no records of the species were made for nearly two decades after, signifying low population densities.
Infrequent sightings only served to buttress the belief that the giant crustacean was rare.
There have been only seven studies so far detailing the DNA sequence data of the species.
The latest study, published in the journal Royal Society Open Science, analyses nearly 200 records of Alicella gigantea from 75 locations on the seabed, spanning the Pacific, Atlantic and Indian Oceans.
Researchers from the University of Western Australia now suggest the species may well be inhabiting over half the world's deep oceans.
The study notes the crustacean thrives at extreme depths in 59 per cent of the world's oceans, indicating that it is far more widespread than previously thought.
The research examines 195 records of the supergiant species, including genetic data from mitochondrial and nuclear DNA, from 75 locations worldwide to map its distribution and evolutionary history.
It concludes that while the creature is rarely collected, it is 'remarkably widespread'.
'There is an ever-growing body of evidence to show that A gigantea should be considered far from rare,' the research says.
Although the crustacean's population density may be relatively low compared to other deep-sea amphipods, it inhabits an extraordinarily large geographical range, researchers say.
'Our results show that this species may occupy around 59 per cent of the world's oceans, indicating that the infrequently collected supergiant isn't 'rare' but instead represents a widely distributed deep-sea amphipod with an exceptional global range,' they write.
The findings also point to insufficient research of creatures inhabiting the ocean at depths greater than 5,000m. This is in line with another recent study finding that humans have observed less than 0.001 per cent of the deep seafloor.
'We need a much better understanding of the deep ocean's ecosystems and processes to make informed decisions about resource management and conservation,' study lead author and marine explorer Katy Croff Bell says.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
2 hours ago
- Medical News Today
Colon cancer: Adding immunotherapy may halve death, recurrence rate
Combining immunotherapy nd chemotherapy may give better results for treating colon cancer, research shows. wilpunt/Getty Images While there are several treatment options for colon cancer, not all of them work for all cancer types. Deficient mismatch repair (dMMR) colon cancer is known to be less responsive to chemotherapy than other types. A new study reports that adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease a person's recurrence and death rate by half. However, not all treatments work for all types of colorectal cancer. For example, deficient mismatch repair (dMMR) colon cancer , which is caused by mutations in genes that correct mistakes that happen when a person's DNA is copied, encompasses 5-15% of colorectal cancer cases and may not be as responsive to chemotherapy as other types. Now, a new study presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting reports that adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease a person's recurrence and death rate by half. The findings are yet to be published in a peer-reviewed journal. For this phase III clinical trial, researchers recruited 712 people with an average age of 64 who had dMMR stage 3 colon cancer. This stage of colorectal cancer occurs when the cancer spreads to the body's lymph nodes, but nowhere else. All study participants had undergone surgery to have their cancer removed and still had cancer cells in their lymph nodes. Atezolizumab targets a specific protein in cancer cells called programmed death-ligand 1 (PD-L1) . PD-L1's job is to keep cancer cells 'hidden' from detection by the body's immune system. By binding and blocking to PD-L1, atezolizumab makes the cancer cells 'visible' to the immune system so it can attack them. At the study's conclusion, researchers found that participants receiving chemotherapy with immunotherapy had a 50% decrease in cancer recurrence and death — known as disease-free survival (DFS) — compared to those who only received chemotherapy. 'The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer,' says Frank Sinicrope, MD, oncologist at the Mayo Clinic in Minnesota and lead author of this study, in a press release. 'It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival,' he says. 'We're changing the paradigm in colon cancer treatment. By using immunotherapy at earlier stages of disease, we are achieving meaningful benefits for our patients.' — Frank Sinicrope, MD Medical News Today spoke with Glenn S. Parker, MD, FACS, FASCRS, vice chairman of surgery and chief of colorectal surgery at Hackensack Meridian Jersey Shore University Medical Center in New Jersey, about this study who commented that his first reaction to these findings was a strong sense of hope. 'The use of atezolizumab, an immune checkpoint inhibitor, alongside standard chemotherapy in stage III dMMR colon cancer represents a significant step forward in the care of our patients,' Parker explained. 'Patients with dMMR colon cancer often have a distinct tumor biology that affects how they respond to chemotherapy. Although they generally have a better prognosis, recurrence still occurs, and current treatments may not be optimal for this group.' 'Developing therapies that work with the immune system, like atezolizumab, could specifically target the molecular genetics of dMMR tumors and significantly reduce the chance of cancer returning, leading to better long-term outcomes.' — Glenn S. Parker, MD, FACS, FASCRS Parker said he would like to see extended follow-up from the clinical trial to evaluate long-term survival and recurrence data. 'Additionally, further studies should explore whether immunotherapy could eventually reduce the length of time for both adjuvant chemotherapy/immunotherapy in some dMMR patients, particularly those with high immune activation profiles,' he continued. 'Biomarker analyses and quality-of-life assessments will also be critical in determining which patients benefit the most from combined therapy and how best to integrate this approach into standard of care,' he added. MNT also spoke with Wael Harb, MD, a board certified hematologist and medical oncologist at MemorialCare Cancer Institute at Orange Coast and Saddleback Medical Centers in Orange County, CA, about this research, who said he was genuinely excited by the trial's results. 'Colon cancer is one of the most common and deadly cancers worldwide,' he continued. 'Even after surgery, many patients — especially those with stage III disease — face a real risk that their cancer will return. For people with dMMR tumors, traditional chemotherapy doesn't always offer enough protection. What makes this group unique is that their tumors are especially responsive to immunotherapy. So finding new ways — like this study — to harness the immune system gives us a much better shot at keeping the cancer from coming back,' Harb explained. 'This study is a major step forward for patients with stage III colon cancer who have a specific genetic feature called dMMR. The combination of standard chemotherapy with the immunotherapy drug atezolizumab cut the risk of cancer recurrence and death by 50%. That's a dramatic improvement — and in the world of cancer care, results like these can lead to real changes in how we treat patients. It's the kind of data that could redefine the standard of care.' — Wael Harb, MD Harb said the most important next step for this research is to see this approach integrated into treatment guidelines, so doctors everywhere can offer it to eligible patients. 'I'd also like to see longer-term follow-up data to confirm the durability of benefit and monitor safety over time. And looking ahead, it would be exciting to explore whether immunotherapy could also help patients with earlier-stage disease — or even be used instead of chemotherapy in some cases. Ultimately, this study opens the door to more personalized and effective treatments for colon cancer,' he added. Colorectal Cancer Cancer / Oncology Immune System / Vaccines
The Independent
3 hours ago
- The Independent
The city-killing asteroid swarm hiding near Earth's neighbouring planet
A new study warns that a swarm of large, undiscovered asteroids near Venus could pose a future threat to Earth. These co-orbital asteroids, likely originating from the main asteroid belt between Mars and Jupiter, are estimated to be over 140 metres in size, capable of causing city-sized damage upon impact. Scientists have discovered around 20 asteroids orbiting Venus, but suspect many more remain hidden due to the Sun's glare. Computer simulations suggest that these hidden asteroids could change trajectories, potentially leading to a collision course with Earth over millennia. Researchers hope the Rubin Observatory and future Venus-based space missions will help detect these obscured asteroids and better assess the risk they pose.
The Independent
5 hours ago
- The Independent
How fruit peels could be used to jump-start your car
Imagine turning fruit waste into technology that stores electricity. This would reduce food waste and promote clean energy storage. Postdoctoral researcher Vianney Ngoyi Kitenge transformed mangosteen peels into specialised carbon materials that he used to make supercapacitor energy storage cells. He came up with a simplified way to do this, hugely reducing the cost. This breakthrough converts agricultural waste into valuable components for energy storage technology. He sets out how it works and what's needed to make it happen. What is a supercapacitor? Supercapacitors are a type of energy storage cell, similar to a battery, but with some key differences. They are standalone devices that store and release energy on their own. The biggest difference between a supercapacitor and a battery is how quickly a supercapacitor can charge and release energy. While batteries are designed to provide energy steadily over a longer period (like minutes or hours), supercapacitors are built to deliver energy very quickly – within seconds or minutes. This makes them perfect for applications that need a quick burst of power. You probably use supercapacitors every day without realising it. They help devices like flashes in your smartphone camera, portable jump starters for cars, fitness trackers, and smartwatches that need quick energy boosts to work efficiently. When making devices, the manufacturers choose whether to use a battery or a supercapacitor. This decision is based on how much power is needed and how fast it's needed. Most of the time, consumers aren't even aware of whether there's a battery or supercapacitor inside their devices. In energy storage cells where electrical charges are stored, electrodes are key. Supercapacitors' electrodes can be made with activated carbon. This can be made from biomass waste, such as coconut shells, banana peels, mangosteen peels, and coffee grounds. I used mangosteen peels in my research. What are supercapacitors used for? Apart from camera flashes and emergency doors, supercapacitors are useful in renewable energy. They act like super-fast energy sponges that can quickly soak up extra electricity when solar panels or wind turbines produce too much. They can also quickly release this energy when too little is produced. This helps keep the power flow steady even when it's not sunny or windy. Supercapacitors are still a small player in the energy storage world, with sales at around US$3 billion to US$4 billion yearly. To put this in perspective, the sales of lithium-ion batteries are US$50 billion to US$60 billion annually. Most are made in China and Japan, with some production in Europe and America, too. Supercapacitors haven't caught on widely yet. This is why scientists continue to work to increase supercapacitors' total energy storage while maintaining their speed and longevity. What role can mangosteen peels play? There has been little research into using the peels of the mangosteen fruit to create carbon. Yet, mangosteen trees grow abundantly from the east coast of South Africa to Somalia and Guinea, and they can withstand drought and rainstorms. Their peels naturally contain 35%-45% carbon-rich compounds. When processed through drying, oxygen-free heating and chemical activation, these peels transform into activated carbon. Through my research, I developed a simplified method to transform mangosteen shells into highly porous activated carbon. By combining the dried shells with potassium carbonate and directly heating to 700°C in a single step, I created valuable activated carbon from agricultural waste. Usually, creating activated carbon is a longer process of pre-heating fruit peels and reheating. So my method speeds the process up. This faster method makes activated carbon much cheaper by eliminating the initial five-hour heating phase at 400-500°C. This saves on electricity and reduces both production costs and the amount of time the furnace needs to operate. This then makes it more affordable for widespread commercial use. Using fruit peels to create activated carbon also prevents them from being dumped on landfill sites and instead uses them to make valuable energy storage devices. Just three to five kilograms of fruit peels are enough to produce hundreds of supercapacitors. The global demand for supercapacitors is projected to grow significantly over the coming decade. This demand will be driven primarily by electric vehicles, renewable energy systems, and consumer electronics markets seeking high-power, rapid-cycling energy storage solutions. Citrus peels can also be used to make activated carbon. Worldwide, the citrus juice industry generates 15 million tonnes of wasted peels, pulp and seeds every year. This waste could be used to make supercapacitors. What's needed to make this happen? Some companies are already turning food and agricultural waste into activated carbon. For example, Haycarb, based in Sri Lanka, turns coconut shells into activated carbon. Takachar in the US is also developing small-scale technology to turn agricultural waste into useful products like activated carbon. In Africa, fruit processing plants could set up facilities to turn their waste into activated carbon. They could then sell it to energy storage companies or other industries that need it. To make this happen, experts are needed to further develop the science. Governments and the private sector will need to fund equipment and facilities. Then, the factories making supercapacitors need to be connected with industries that could buy them (electric vehicles, renewable energy and electronics manufacturers). Making supercapacitors from fruit peels could create jobs and support Africa's renewable energy goals.
